Article Information
History
- August 23, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Harvey W Kaufman, MD1,
- William A Meyer III, PhD1,
- Nigel J Clarke, PhD1,
- Jeff Radcliff, BS1,
- Christopher M Rank, PhD2,
- James Freeman, BS3,
- Marcia Eisenberg, PhD4,
- Laura Gillim, PhD4,
- William G Morice, MD, PhD5,
- David M Briscoe, MD6,
- David S Perlin, PhD7 and
- Jay G Wohlgemuth, MD1,*
- 1Quest Diagnostics, 500 Plaza Drive, Secaucus, NJ 07940
- 2Roche Diagnostics Nonnenwald 2, 82377 GmbH, Penzberg, Germany
- 3Siemens Healthineers, 511 Benedict Ave, Tarrytown, New York 10591
- 4LabCorp, 531 South Spring Street Burlington, NC 27215
- 5Mayo Medical Laboratories, 3050 Superior Dr., NW Rochester, MN, 55905
- 6Boston Children’s Hospital, 300 Longwood Ave., Boston, MA 02115
- 7Center for Discovery and Innovation, Hackensack Meridian Health, 111 Ideation Way, Nutley, NJ 07110
- ↵*Correspondence:
Dr. Jay G Wohlgemuth, Chief Medical Officer and Senior VP R&D, Medical and Population Health, Quest Diagnostics, 33608 Ortega Highway, San Juan Capistrano, CA 92675, Mobile +1.949.491.2698, Jay.G.Wohlgemuth{at}questdiagnostics.com
Posted August 23, 2022.
Assessing Vulnerability to COVID-19 in High-Risk Populations: The Role of SARS-CoV-2 Spike-Targeted Serology
